• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孤立性单侧眼眶转移:源自于 FDG PET/CT 扫描的尤文肉瘤。

Isolated Unilateral Orbital Metastasis From Ewing Sarcoma Detected on FDG PET/CT Scan.

机构信息

From the Department of Opthalmology, Saraswathi Institute of Medical Sciences, Anwarpur, Uttar Pradesh.

Department of Nuclear Medicine and PET/CT, Platinum Imaging Centre.

出版信息

Clin Nucl Med. 2021 Jul 1;46(7):e391-e392. doi: 10.1097/RLU.0000000000003546.

DOI:10.1097/RLU.0000000000003546
PMID:33630799
Abstract

Ewing sarcoma is the second most common primary malignant bone tumor that usually affects diaphysis of long bones during the second decade of life. Isolated unilateral orbital metastasis from this tumor presenting as proptosis is extremely rare. Here we report a case of 11-year-old boy where whole-body FDG PET/CT scan detected primary an Ewing sarcoma site in the left femur and isolated orbital metastasis in the left eye. Follow-up PET/CT scan after 6 cycles of chemotherapy showed resolution of the previously seen lesions.

摘要

尤因肉瘤是第二常见的原发性骨恶性肿瘤,通常发生在生命的第二个十年,影响长骨的骨干。这种肿瘤孤立性单侧眼眶转移并表现为眼球突出极为罕见。在此我们报告一例 11 岁男孩,全身 FDG PET/CT 扫描发现左侧股骨有原发性尤因肉瘤病灶和左眼孤立性眼眶转移。6 个周期化疗后的随访 PET/CT 扫描显示先前所见病变已消退。

相似文献

1
Isolated Unilateral Orbital Metastasis From Ewing Sarcoma Detected on FDG PET/CT Scan.孤立性单侧眼眶转移:源自于 FDG PET/CT 扫描的尤文肉瘤。
Clin Nucl Med. 2021 Jul 1;46(7):e391-e392. doi: 10.1097/RLU.0000000000003546.
2
What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?18F-FDG PET/CT、99mTc-MDP 骨显像和全身 MRI 作为分期检查在检测骨肉瘤和尤文肉瘤患者骨转移中的比较能力如何?
Clin Orthop Relat Res. 2021 Aug 1;479(8):1768-1779. doi: 10.1097/CORR.0000000000001681.
3
Adamantinoma-Like Ewing Sarcoma of the Mandible Evaluated on 18F-FDG PET/CT.下颌骨 18F-FDG PET/CT 评估似造釉细胞瘤样尤文肉瘤。
Clin Nucl Med. 2022 Jul 1;47(7):635-637. doi: 10.1097/RLU.0000000000004195. Epub 2022 Apr 5.
4
Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma.18F-FDG PET/CT在尤因肉瘤患儿化疗分期及疗效评估中的诊断准确性
J Pediatr Hematol Oncol. 2018 May;40(4):277-284. doi: 10.1097/MPH.0000000000001135.
5
18F-FDG PET/CT of Primary Extraskeletal Ewing Sarcoma of the Prostate.18F-FDG PET/CT 于前列腺原发性骨外尤文肉瘤的应用。
Clin Nucl Med. 2022 Dec 1;47(12):e754-e755. doi: 10.1097/RLU.0000000000004392. Epub 2022 Sep 6.
6
Cardiac metastases of Ewing sarcoma detected by 18F-FDG PET/CT.18F-FDG PET/CT检测到的尤因肉瘤心脏转移灶。
J Pediatr Hematol Oncol. 2012 Apr;34(3):236-8. doi: 10.1097/MPH.0b013e318242754d.
7
F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma.氟代脱氧葡萄糖正电子发射断层扫描-计算机断层扫描与磁共振成像在尤文肉瘤骨转移检测中的比较。
Skeletal Radiol. 2019 Nov;48(11):1735-1746. doi: 10.1007/s00256-019-03192-2. Epub 2019 Apr 23.
8
Recurrent Metastatic Ewing Sarcoma Involving Only in the Muscles of Extremities Shown on FDG PET/CT.仅累及四肢肌肉的复发性转移性尤文肉瘤在 FDG PET/CT 上的表现。
Clin Nucl Med. 2024 Jun 1;49(6):589-591. doi: 10.1097/RLU.0000000000005202. Epub 2024 Mar 25.
9
An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.评估 [F-18]-氟代脱氧-D-葡萄糖正电子发射断层扫描、骨扫描、骨髓抽吸/活检在尤因肉瘤分期中的作用。
Pediatr Blood Cancer. 2013 Jul;60(7):1113-7. doi: 10.1002/pbc.24406. Epub 2012 Nov 28.
10
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on F-fluorodeoxyglucose positron emission tomography/computed tomography.基于 F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的无转移尤文肉瘤/外周原始神经外胚层肿瘤患者的骨髓检查。
Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.